

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/077032 A1

(51) International Patent Classification:

C07K 14/82 (2006.01) C12N 5/0783 (2010.01)
C07K 19/00 (2006.01) G01N 33/50 (2006.01)

(21) International Application Number:

PCT/US2022/078825

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/263,233	28 October 2021 (28.10.2021)	US
63/309,403	11 February 2022 (11.02.2022)	US
63/339,353	06 May 2022 (06.05.2022)	US

(71) Applicant: **LYELL IMMUNOPHARMA, INC.**
[US/US]; 201 Haskins Way, South San Francisco, California 94080 (US).

(72) Inventors: **VODNALA, Suman Kumar**; c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080 (US). **KRISHNAMOORTHY, Veena**; c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080 (US). **PARK, Spencer**; c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080 (US). **VONG, Queenie**; c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080 (US). **SATHER, Blythe**; c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080 (US).

(74) Agent: **STEFFE, Eric K.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR CULTURING CELLS EXPRESSING C-JUN

(57) Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.

WO 2023/077032 A1